Clinical Trials · NCT00690430

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Name: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Octreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Novartis Pharmaceuticals
Enrollment: 186
Start date: Apr 2008
Locations: 62 sites, 16 countries
Primary endpoint: Percentage of Patients Who Achieved Clinical Symptom Improvement by Randomization Stratum and Treatment.

View Octreotide compound reference